These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 25598013

  • 1. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
    Franciosi AN, McCarthy C, McElvaney NG.
    Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
    [Abstract] [Full Text] [Related]

  • 2. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
    Edgar RG, Patel M, Bayliss S, Crossley D, Sapey E, Turner AM.
    Int J Chron Obstruct Pulmon Dis; 2017 Apr; 12():1295-1308. PubMed ID: 28496314
    [Abstract] [Full Text] [Related]

  • 3. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S, Camprubi S, Griffin R, Chen J, Ayguasanosa J.
    Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
    Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR.
    Int J Chron Obstruct Pulmon Dis; 2012 Apr; 7():687-96. PubMed ID: 23055718
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
    Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr; 13():419-432. PubMed ID: 29430176
    [Abstract] [Full Text] [Related]

  • 10. Alpha-1-antitrypsin and other proteinase inhibitors.
    Miravitlles M.
    Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
    [Abstract] [Full Text] [Related]

  • 11. Alpha-1 antitrypsin augmentation therapy.
    Wewers MD, Crystal RG.
    COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
    [Abstract] [Full Text] [Related]

  • 12. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update.
    Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, Hernández JM, Lázaro L, Rodríguez E, Rodríguez-Frías F, Torres M, Lara B.
    Arch Bronconeumol; 2015 Apr; 51(4):185-92. PubMed ID: 25027067
    [Abstract] [Full Text] [Related]

  • 13. New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency.
    Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, Greulich T, Sandhaus RA, Campos M.
    Int J Chron Obstruct Pulmon Dis; 2020 Apr; 15():345-355. PubMed ID: 32103933
    [Abstract] [Full Text] [Related]

  • 14. Augmentation therapy in alpha-1 antitrypsin deficiency.
    Heresi GA, Stoller JK.
    Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
    [Abstract] [Full Text] [Related]

  • 15. Delivery of Alpha-1 Antitrypsin to Airways.
    Griese M, Scheuch G.
    Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S346-51. PubMed ID: 27564672
    [Abstract] [Full Text] [Related]

  • 16. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route.
    Hubbard RC, Crystal RG.
    Lung; 1990 Aug; 168 Suppl():565-78. PubMed ID: 2117165
    [Abstract] [Full Text] [Related]

  • 17. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment.
    Monk R, Graves M, Williams P, Strange C.
    COPD; 2013 Aug; 10(4):411-5. PubMed ID: 23537112
    [Abstract] [Full Text] [Related]

  • 18. Safety of biweekly α1-antitrypsin treatment in the RAPID programme.
    Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG, RAPID Trial Group.
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30237305
    [Abstract] [Full Text] [Related]

  • 19. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
    Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG, RAPID Trial Study Group.
    Lancet; 2015 Jul 25; 386(9991):360-8. PubMed ID: 26026936
    [Abstract] [Full Text] [Related]

  • 20. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.
    O'Brien ME, Fee L, Browne N, Carroll TP, Meleady P, Henry M, McQuillan K, Murphy MP, Logan M, McCarthy C, McElvaney OJ, Reeves EP, McElvaney NG.
    Thorax; 2020 Apr 25; 75(4):321-330. PubMed ID: 31959730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.